ARVN
Price
$8.05
Change
-$0.09 (-1.11%)
Updated
Jun 24 closing price
Capitalization
519.4M
35 days until earnings call
Intraday BUY SELL Signals
CLDX
Price
$33.78
Change
+$0.80 (+2.43%)
Updated
Jun 24 closing price
Capitalization
2.65B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARVN vs CLDX

ARVN vs CLDX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARVN vs. CLDX commentary
Jun 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and CLDX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 25, 2026
Stock price -- (ARVN: $8.05 vs. CLDX: $32.98)
Brand notoriety: ARVN and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 81% vs. CLDX: 82%
Market capitalization -- ARVN: $519.4M vs. CLDX: $2.65B
ARVN [@Biotechnology] is valued at $519.4M. CLDX’s [@Biotechnology] market capitalization is $2.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $120.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARVN is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 4 TA indicator(s) are bullish while CLDX’s TA Score has 6 bullish TA indicator(s).

  • ARVN’s TA Score: 4 bullish, 5 bearish.
  • CLDX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than ARVN.

Price Growth

ARVN (@Biotechnology) experienced а +4.95% price change this week, while CLDX (@Biotechnology) price change was +2.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.42%. For the same industry, the average monthly price growth was +1.98%, and the average quarterly price growth was +1906.15%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 30, 2026.

CLDX is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+3.42% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($2.65B) has a higher market cap than ARVN($519M). CLDX YTD gains are higher at: 24.448 vs. ARVN (-32.125). ARVN has higher annual earnings (EBITDA): -248.7M vs. CLDX (-305.7M). ARVN has more cash in the bank: 615M vs. CLDX (451M). CLDX has less debt than ARVN: CLDX (1.91M) vs ARVN (8.4M). ARVN has higher revenues than CLDX: ARVN (89.4M) vs CLDX (865K).
ARVNCLDXARVN / CLDX
Capitalization519M2.65B20%
EBITDA-248.7M-305.7M81%
Gain YTD-32.12524.448-131%
P/E RatioN/AN/A-
Revenue89.4M865K10,335%
Total Cash615M451M136%
Total Debt8.4M1.91M440%
FUNDAMENTALS RATINGS
ARVN vs CLDX: Fundamental Ratings
ARVN
CLDX
OUTLOOK RATING
1..100
928
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
82
Overvalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
6443
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for CLDX (82). This means that ARVN’s stock grew somewhat faster than CLDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as ARVN (100). This means that CLDX’s stock grew similarly to ARVN’s over the last 12 months.

CLDX's SMR Rating (99) in the Biotechnology industry is in the same range as ARVN (99). This means that CLDX’s stock grew similarly to ARVN’s over the last 12 months.

CLDX's Price Growth Rating (43) in the Biotechnology industry is in the same range as ARVN (64). This means that CLDX’s stock grew similarly to ARVN’s over the last 12 months.

CLDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ARVN (100). This means that CLDX’s stock grew similarly to ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNCLDX
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
79%
Bearish Trend 17 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ARVN
Daily Signal:
Gain/Loss:
CLDX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MMID25.86N/A
N/A
MFS Active Mid Cap ETF
NBH10.45-0.01
-0.10%
Neuberger Municipal Fund Inc.
XDIV29.94-0.04
-0.15%
Roundhill S&P 500 No Dividend Target ETF
FAS148.51-1.38
-0.92%
Direxion Daily Financial Bull 3X ETF
MLPR66.41-2.86
-4.13%
ETRACS Qrtly Py 1.5X Lvgd Aln MLP ETN

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+2.49%
KURA - CLDX
49%
Loosely correlated
+2.36%
XNCR - CLDX
49%
Loosely correlated
+2.70%
VYGR - CLDX
48%
Loosely correlated
-0.54%
VIR - CLDX
48%
Loosely correlated
-2.07%
BCAX - CLDX
47%
Loosely correlated
+2.56%
More